Apolipoproteins inhibit the innate immunity activated by necrotic cells or bacterial endotoxin

Immunology

Volumn 128, Issue 1 PART 2, 2009, Pages

  Cho, Nam Hyuk ^a   Seong, Seung Yong ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Apolipoproteins; Complement; Endotoxin; Innate immunity; Necrotic cell

Indexed keywords

APOLIPOPROTEIN; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DENDRITIC CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; INNATE IMMUNITY; LIPID METABOLISM; LIPID TRANSPORT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD40; APOLIPOPROTEINS; CHO CELLS; COMPLEMENT ACTIVATION; CRICETINAE; CRICETULUS; DENDRITIC CELLS; FIBROBLASTS; IMMUNITY, INNATE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NECROSIS; NF-KAPPA B; TOLL-LIKE RECEPTOR 2;

EID: 68249136804     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.03002.x     Document Type: Article

References (37)

1. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004 4 : 469 78.
2. Janeway CA Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002 20 : 197 216.
3. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001 13 : 114 9.
4. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007 19 : 3 10.
5. Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006 11 : 1709 26.
6. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002 418 : 191 5.
7. Tanimoto N, Terasawa M, Nakamura M, Kegai D, Aoshima N, Kobayashi Y, Nagata K. Involvement of KC, MIP-2, and MCP-1 in leukocyte infiltration following injection of necrotic cells into the peritoneal cavity. Biochem Biophys Res Commun 2007 361 : 533 6.
8. Berger D, Schleich S, Seidelmann M, Beger HG. Correlation between endotoxin-neutralizing capacity of human plasma as tested by the limulus-amebocyte-lysate-test and plasma protein levels. FEBS Lett 1990 277 : 33 6.
9. Berbee JF, Havekes LM, Rensen PC. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 2005 11 : 97 103.
10. Furlaneto CJ, Ribeiro FP, Hatanaka E, Souza GM, Cassatella MA, Campa A. Apolipoproteins A-I and A-II downregulate neutrophil functions. Lipids 2002 37 : 925 8.
11. Williams KJ, Feig JE, Fisher EA. Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. Curr Opin Lipidol 2007 18 : 443 50.
12. Medvedev AE, Henneke P, Schromm A, Lien E, Ingalls R, Fenton MJ, Golenbock DT, Vogel SN. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol 2001 167 : 2257 67.
13. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999 5 : 1249 55.
14. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002 23 : 509 12.
15. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004 76 : 514 9.
16. Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, Ouaaz F, Medzhitov RM, Beg AA. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001 166 : 7128 35.
17. Heine H, Kirschning CJ, Lien E, Monks BG, Rothe M, Golenbock DT. Cutting edge: cells that carry A null allele for toll-like receptor 2 are capable of responding to endotoxin. J Immunol 1999 162 : 6971 5.
18. Seong SY. A missed proteome in living organisms: a Hyppo system. Curr Proteomics 2006 3 : 129 46.
19. Marcel YL, Kiss RS. Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations. Curr Opin Lipidol 2003 14 : 151 7.
20. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000 18 : 767 811.
21. Ciurana CL, Zwart B, van Mierlo G, Hack CE. Complement activation by necrotic cells in normal plasma environment compares to that by late apoptotic cells and involves predominantly IgM. Eur J Immunol 2004 34 : 2609 19.
22. Gaipl US, Kuenkele S, Voll RE, Beyer TD, Kolowos W, Heyder P, Kalden JR, Herrmann M. Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ 2001 8 : 327 34.
23. Xu W, Berger SP, Trouw LA, de Boer HC, Schlagwein N, Mutsaers C, Daha MR, van Kooten C. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol 2008 180 : 7613 21.
24. Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, Gasque P. CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 2005 280 : 36342 54.
25. Gaipl US, Sheriff A, Franz S, Munoz LE, Voll RE, Kalden JR, Herrmann M. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 2006 305 : 161 76.
26. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 2002 1 : 111 7.
27. Garber DW, Handattu SP, Datta G, Mishra VK, Gupta H, White CR, Anantharamaiah GM. Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins. Curr Pharm Biotechnol 2006 7 : 235 40.
28. Bresnihan B, Gogarty M, FitzGerald O, Dayer JM, Burger D. Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res Ther 2004 6 : R563 6.
29. Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 2005 46 : 949 68.
30. Ma J, Liao XL, Lou B, Wu MP. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim Biophys Sin (Shanghai) 2004 36 : 419 24.
31. Gupta H, Dai L, Datta G et al. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 2005 97 : 236 43.
32. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003 92 : 330 7.
33. Chiesa G, Parolini C, Sirtori CR. Acute effects of high-density lipoproteins: biochemical basis and clinical findings. Curr Opin Cardiol 2008 23 : 379 85.
34. Yan YJ, Li Y, Lou B, Wu MP. Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci 2006 79 : 210 5.
35. Jiao YL, Wu MP. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 2008 43 : 83 7.
36. Bottcher A, Gaipl US, Furnrohr BG, Herrmann M, Girkontaite I, Kalden JR, Voll RE. Involvement of phosphatidylserine, alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes by macrophages. Arthritis Rheum 2006 54 : 927 38.
37. Sim RB, Kishore U, Villiers CL, Marche PN, Mitchell DA. C1q binding and complement activation by prions and amyloids. Immunobiology 2007 212 : 355 62.